FDA Approves Alyftrek, Once-Daily CFTR Modulator for Cystic Fibrosis
Pharmacy Times
DECEMBER 21, 2024
The approval comes after clinical trial results in which vanzacaftor/tezacaftor/deutivacaftor (Alyftrek; Vertex Pharmaceuticals) demonstrated superiority compared with elexacaftor/tezacaftor/ivacaftor and ivacaftor (Trikafta; Vertex Pharmaceuticals).
Let's personalize your content